Company Description
Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates.
The company's therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
It also develops INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company.
Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.
| Country | United States |
| Founded | 2010 |
| IPO Date | Aug 19, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 172 |
| CEO | Mark Paul Lappe |
Contact Details
Address: 11025 N. Torrey Pines Road, Suite 200 La Jolla, California 92037 United States | |
| Phone | (858) 795-4220 |
| Website | inhibrx.com |
Stock Details
| Ticker Symbol | INBX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001739614 |
| CUSIP Number | 45720L107 |
| ISIN Number | US45720L1070 |
| Employer ID | 82-4257312 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Mark Paul Lappe | Founder, Chairman, President and Chief Executive Officer |
| Dr. Brendan P. Eckelman Ph.D. | Founder and Chief Scientific Officer |
| Kelly Devine Deck B.S., CPA, M.S. | Executive Vice President and Chief Financial Officer |
| Quinn L. Deveraux | Founder |
| Dr. Ashraf Amanullah | Executive Vice President and Chief Technical Operations Officer |
| Leah Pollema J.D. | Vice President, Corporate Secretary and General Counsel |
| Dr. Charbel Helaihel Pharm.D. | Vice President of Marketing and Commercial Planning |
| Jeffrey J. Jensen | Executive Vice President and Chief Clinical Operations Officer |
| David Matly M.B.A. | Executive Vice President and Chief Commercial and Business Development Officer |
| Dr. Carlos Bais Ph.D. | Executive Vice President of Translational Sciences |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 17, 2024 | 8-K | Current Report |
| May 17, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 9, 2024 | 8-K | Current Report |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 8, 2024 | 8-K | Current Report |
| May 6, 2024 | 144 | Filing |
| Apr 26, 2024 | DEFM14A | Filing |
| Mar 26, 2024 | 144 | Filing |
| Mar 22, 2024 | 144 | Filing |
| Mar 21, 2024 | 144 | Filing |